Literature DB >> 17616669

MicroRNA expression profiling in prostate cancer.

Kati P Porkka1, Minja J Pfeiffer, Kati K Waltering, Robert L Vessella, Teuvo L J Tammela, Tapio Visakorpi.   

Abstract

MicroRNAs (miRNA) are small, endogenously expressed noncoding RNAs that negatively regulate expression of protein-coding genes at the translational level. Accumulating evidence, such as aberrant expression of miRNAs, suggests that they are involved in the development of cancer. They have been identified in various tumor types, showing that different sets of miRNAs are usually deregulated in different cancers. To identify the miRNA signature specific for prostate cancer, miRNA expression profiling of 6 prostate cancer cell lines, 9 prostate cancer xenografts samples, 4 benign prostatic hyperplasia (BPH), and 9 prostate carcinoma samples was carried out by using an oligonucleotide array hybridization method. Differential expression of 51 individual miRNAs between benign tumors and carcinoma tumors was detected, 37 of them showing down-regulation and 14 up-regulation in carcinoma samples, thus identifying those miRNAs that could be significant in prostate cancer development and/or growth. There was a significant trend (P=0.029) between the expression of miRNAs and miRNA locus copy number determined by array comparative genomic hybridization, indicating that genetic aberrations may target miRNAs. Hierarchical clustering of the tumor samples by their miRNA expression accurately separated the carcinomas from the BPH samples and also further classified the carcinoma tumors according to their androgen dependence (hormone naive versus hormone refractory), indicating the potential of miRNAs as a novel diagnostic and prognostic tool for prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17616669     DOI: 10.1158/0008-5472.CAN-07-0533

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  397 in total

1.  MicroRNA-224 and its target CAMKK2 synergistically influence tumor progression and patient prognosis in prostate cancer.

Authors:  Hao Fu; Hui-chan He; Zhao-dong Han; Yue-ping Wan; Hong-wei Luo; Ya-qiang Huang; Chao Cai; Yu-xiang Liang; Qi-shan Dai; Fu-neng Jiang; Wei-de Zhong
Journal:  Tumour Biol       Date:  2014-11-15

2.  Differentiation of prostate cancer cells using flexible fluorescent polymers.

Authors:  Michael D Scott; Rinku Dutta; Manas K Haldar; Bin Guo; Daniel L Friesner; Sanku Mallik
Journal:  Anal Chem       Date:  2011-12-14       Impact factor: 6.986

3.  MicroRNAs as new players in the genomic galaxy and disease puzzles.

Authors:  Elisa Barbarotto; Paola Secchiero; Abhijit Dasgupta; Paolo Fortina; George A Calin; Terry Hyslop
Journal:  Clin Transl Sci       Date:  2008-05       Impact factor: 4.689

Review 4.  Implication of microRNAs in drug resistance for designing novel cancer therapy.

Authors:  Fazlul H Sarkar; Yiwei Li; Zhiwei Wang; Dejuan Kong; Shadan Ali
Journal:  Drug Resist Updat       Date:  2010-03-17       Impact factor: 18.500

5.  Identifying functional miRNA-mRNA regulatory modules with correspondence latent dirichlet allocation.

Authors:  Bing Liu; Lin Liu; Anna Tsykin; Gregory J Goodall; Jeffrey E Green; Min Zhu; Chang Hee Kim; Jiuyong Li
Journal:  Bioinformatics       Date:  2010-10-17       Impact factor: 6.937

6.  Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.

Authors:  C Coarfa; W Fiskus; V K Eedunuri; K Rajapakshe; C Foley; S A Chew; S S Shah; C Geng; J Shou; J S Mohamed; B W O'Malley; N Mitsiades
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

Review 7.  Missing link between microRNA and prostate cancer.

Authors:  Balraj Singh Gill; Jimi Marin Alex; Sanjeev Kumar
Journal:  Tumour Biol       Date:  2016-01-28

8.  miRNA Expression Analyses in Prostate Cancer Clinical Tissues.

Authors:  Nathan Bucay; Varahram Shahryari; Shahana Majid; Soichiro Yamamura; Yozo Mitsui; Z Laura Tabatabai; Kirsten Greene; Guoren Deng; Rajvir Dahiya; Yuichiro Tanaka; Sharanjot Saini
Journal:  J Vis Exp       Date:  2015-09-08       Impact factor: 1.355

9.  Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic.

Authors:  Ntube N O Ngalame; Erik J Tokar; Rachel J Person; Yuanyuan Xu; Michael P Waalkes
Journal:  Toxicol Sci       Date:  2014-01-15       Impact factor: 4.849

10.  MiR-145 suppresses the motility of prostate cancer cells by targeting cadherin-2.

Authors:  Huixuan Zeng; Yishan Huang; Qiuling Liu; Hongjiao Liu; Tianzhu Long; Cairong Zhu; Xiaoping Wu
Journal:  Mol Cell Biochem       Date:  2021-05-27       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.